Literature DB >> 17460288

Correlation between focal macular electroretinograms and angiographic findings after photodynamic therapy.

Kohei Ishikawa1, Mineo Kondo, Yasuki Ito, Masato Kikuchi, Hiroaki Nishihara, Chang-Hua Piao, Tadasu Sugita, Hiroko Terasaki.   

Abstract

PURPOSE: It is known that the amplitudes of the multifocal electroretinograms are generally reduced soon after photodynamic therapy (PDT). The purpose of this study was to determine whether this amplitude reduction correlates with the changes in macular thickness or with changes in choroidal circulation.
METHODS: Thirty-seven eyes that were successfully treated by PDT were studied. Focal macular electroretinograms (fmERGs) and optical coherence tomography were performed before and 1 week, 1 month, and 3 months after PDT. Indocyanine green angiography was performed before and 3 months after PDT. The indocyanine green angiographic findings were classified into two groups: group A, with indistinct hypofluorescence at the site of the PDT, and group B, with well-defined hypofluorescence borders coinciding with the site of the PDT.
RESULTS: The mean amplitudes of the fmERGs were significantly reduced at 1 week after PDT (P < 0.05). The correlations between the changes in the amplitude of the fmERG and the changes in macular thickness were not significant. Sixteen (43%) of the study eyes were classified into group A and 21 (57%) into group B by indocyanine green angiography. The mean ratio of the fmERG b-wave 1 week after PDT to that before PDT was 1.14 +/- 0.62 in group A and 0.65 +/- 0.29 in group B. This difference was statistically significant (P < 0.01).
CONCLUSIONS: One of the possibilities that could explain the reduction in the amplitude of the fmERGs soon after PDT is the reduction in choroidal circulation caused by the PDT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17460288     DOI: 10.1167/iovs.06-1277

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

1.  Depolarizing focal macular electroretinogram pattern after photodynamic therapy in a patient with polypoidal choroidal vasculopathy.

Authors:  Tomoharu Nishimura; Shigeki Machida; Kunifusa Tamada; Daijirou Kurosaka
Journal:  Jpn J Ophthalmol       Date:  2010-11-05       Impact factor: 2.447

2.  Focal macular electroretinograms after photodynamic therapy combined with intravitreal bevacizumab.

Authors:  Kohei Ishikawa; Hiroaki Nishihara; Shinsuke Ozawa; Chang-Hua Piao; Yasuki Ito; Mineo Kondo; Hiroko Terasaki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-10-31       Impact factor: 3.117

3.  Half-dose photodynamic therapy for chronic central serous chorioretinopathy evaluated by focal macular electroretinograms.

Authors:  Kazuhiro Oiwa; Keiko Kataoka; Ruka Maruko; Shinji Ueno; Yasuki Ito; Hiroko Terasaki
Journal:  Jpn J Ophthalmol       Date:  2017-02-02       Impact factor: 2.447

4.  Two-year results of combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Masaaki Saito; Tomohiro Iida; Mariko Kano; Kanako Itagaki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-04-05       Impact factor: 3.117

5.  Short-term focal macular electroretinogram of eyes treated by aflibercept & photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Kei Takayama; Hiroki Kaneko; Keiko Kataoka; Shinji Ueno; Piao Chang-Hua; Yasuki Ito; Hiroko Terasaki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-08-18       Impact factor: 3.117

6.  Macular function evaluated by focal macular electroretinograms after reduced fluence photodynamic therapy in eyes with polypoidal choroidal vasculopathy.

Authors:  Shigeki Machida; Tomoharu Nishimura; Kunifusa Tamada; Tomomi Harada; Daijiro Kurosaka
Journal:  Doc Ophthalmol       Date:  2011-12-31       Impact factor: 2.379

7.  Photodynamic therapy and central serous chorioretinopathy.

Authors:  Lina Siaudvytyte; Vaida Diliene; Goda Miniauskiene; Vilma Jurate Balciuniene
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2012
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.